This article explores the possibilities and challenges of implementing emerging technologies in the form of Artificial Intelligence in the Pharmaceutical Industry under the current European legal framework governing medicinal products and medical devices. This includes among other things the question, to which degree an AI-programmer or the pharmaceutical manufacturer using such AI can be held liable for damages caused by the decisions of an autonomously acting AI-system.